Regenerative medicine company Juventas Therapeutics [1] is touting the results from 12-month data of a phase 1 clinical trial of heart failure patients. At 12 months, heart failure patients treated with the company’s stem cell therapy showed “significant” improvements in two key measures — a six-minute distance-walking test, as well as the Minnesota Living with Heart Failure Questionnaire [2] , a patient self-assessment of how heart failure affects daily life. Advertisement Dr
Link:
Regenerative medicine company encouraged by heart failure trial